Instil Bio Inc
TIL
Get informed when a big investor buys or sells
+ FollowMarket Cap$50.05M
Close$
$1.00
86.9% downside
Current Fair Value
86.9% downsideOvervalued by 86.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $50.05 Million |
|---|---|
| Enterprise Value | $46.34 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-10.7 |
| Beta | 1.92 |
| Outstanding Shares | 6,781,976 |
Return
| Return on Equity | -28.20% |
|---|---|
| Return on Assets | -15.32% |
| Return on Invested Capital | -20.40% |
Valuation & Multiples
| P/E Ratio | -1.65 |
|---|---|
| PEG | 2.07 |
| Price to Sales | - |
| Price to Book Ratio | 0.51 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -1.17 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$-0.35
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 16, 2026
EPS Estimate
$-0.17
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 28.07%▼ 5.80% |
|---|---|
| Total Invested | $14.64M▼ 22.66% |
| Investors Holding | 25▼ 6.00% |
ESG Score
No data
About Instil Bio Inc
150 employeesInstil Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing an innovative cell therapy pipeline of autologous TIL therapies for the treatment of patients with cancer.